HK1258588A1 - 用於治療眼科疾病的化合物和製劑 - Google Patents

用於治療眼科疾病的化合物和製劑 Download PDF

Info

Publication number
HK1258588A1
HK1258588A1 HK19100945.5A HK19100945A HK1258588A1 HK 1258588 A1 HK1258588 A1 HK 1258588A1 HK 19100945 A HK19100945 A HK 19100945A HK 1258588 A1 HK1258588 A1 HK 1258588A1
Authority
HK
Hong Kong
Prior art keywords
formulations
compounds
ophthalmic diseases
treating ophthalmic
treating
Prior art date
Application number
HK19100945.5A
Other languages
English (en)
Chinese (zh)
Inventor
Jerry CAGLE
Angel Padilla
David Baker
Gary Cook
Harun Takruri
Leah MAKLEY
Emmet CUNNINGHAM
Original Assignee
Viewpoint Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viewpoint Therapeutics, Inc. filed Critical Viewpoint Therapeutics, Inc.
Publication of HK1258588A1 publication Critical patent/HK1258588A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK19100945.5A 2015-09-08 2016-09-08 用於治療眼科疾病的化合物和製劑 HK1258588A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562215629P 2015-09-08 2015-09-08
US201562215629P 2015-09-08
US201562269019P 2015-12-17 2015-12-17
US201562269013P 2015-12-17 2015-12-17
US201562269019P 2015-12-17
US201562269013P 2015-12-17
PCT/US2016/050823 WO2017044659A1 (en) 2015-09-08 2016-09-08 Compounds and formulations for treating ophthalmic diseases

Publications (1)

Publication Number Publication Date
HK1258588A1 true HK1258588A1 (zh) 2019-11-15

Family

ID=58240060

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100945.5A HK1258588A1 (zh) 2015-09-08 2016-09-08 用於治療眼科疾病的化合物和製劑

Country Status (8)

Country Link
US (1) US20180250313A1 (enExample)
EP (1) EP3347368A4 (enExample)
JP (1) JP2018526423A (enExample)
CN (1) CN108350021A (enExample)
AU (1) AU2016321254A1 (enExample)
CA (1) CA2998134A1 (enExample)
HK (1) HK1258588A1 (enExample)
WO (1) WO2017044659A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113234114A (zh) 2011-10-14 2021-08-10 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
WO2014169832A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
MX362543B (es) 2013-04-17 2019-01-24 Sage Therapeutics Inc Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos.
HRP20210610T1 (hr) 2013-07-19 2021-05-28 Sage Therapeutics, Inc. Neuroaktivni steroidi, pripravci i njihove uporabe
PT3035940T (pt) 2013-08-23 2019-01-28 Sage Therapeutics Inc Esteroides neuroativos, composições e seus usos
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3885352B1 (en) 2014-10-16 2024-11-27 Sage Therapeutics, Inc. A compound, compositions thereof and this compound for use in methods of treating cns disorders
EP4275748A3 (en) 2014-10-16 2024-01-03 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
RS60343B1 (sr) 2014-11-27 2020-07-31 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
SMT202100113T1 (it) 2015-01-26 2021-05-07 Sage Therapeutics Inc Composizioni e metodi per trattare disturbi del snc
EP3258939B1 (en) 2015-02-20 2022-09-07 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JP6949838B2 (ja) 2015-10-29 2021-10-13 フィルメニッヒ インコーポレイテッドＦｉｒｍｅｎｉｃｈ Ｉｎｃｏｒｐｏｒａｔｅｄ 高甘味度甘味料
AU2017296295B2 (en) 2016-07-11 2022-02-24 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
JOP20190022B1 (ar) 2016-08-23 2023-03-28 Sage Therapeutics Inc ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري
JP7285786B2 (ja) 2017-05-03 2023-06-02 フィルメニッヒ インコーポレイテッド 高強度の甘味料の製造方法
CN108794556B (zh) * 2017-05-05 2021-01-29 清华大学 化合物及其在治疗白内障中的应用
MY205909A (en) * 2017-06-08 2024-11-20 Eye Therapies Llc Low-dose brimonidine combinations and uses thereof
WO2019097434A1 (en) * 2017-11-17 2019-05-23 Mahmood Piraee Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders
AU2018372826B2 (en) * 2017-11-22 2023-12-07 Bausch & Lomb Incorporated Ophthalmic viscoelastic compositions
US20200276211A1 (en) * 2017-11-28 2020-09-03 Viewpoint Therapeutics, Inc. Compounds for treating near vision disorders
WO2019191200A1 (en) 2018-03-27 2019-10-03 American Genomics, Llc Method and formulation for producing anesthesia of internal aspect of eye wall by topical application
SG11202012473UA (en) * 2018-06-27 2021-01-28 Cellix Bio Private Ltd Ophthalmic compositions and methods for the treatment of eye disorders
US12286661B2 (en) 2018-11-07 2025-04-29 Firmenich Incorporated Methods for making high intensity sweeteners
JP2022512931A (ja) 2018-11-07 2022-02-07 フィルメニッヒ インコーポレイテッド 高甘味度甘味料の製造方法
AU2020245203A1 (en) * 2019-03-26 2021-11-11 Martin Uram Anesthetic composition and method of anesthetizing the eye
AR119047A1 (es) 2019-05-31 2021-11-17 Sage Therapeutics Inc Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc
WO2021113411A1 (en) * 2019-12-02 2021-06-10 Ampersand Biopharmaceuticals, Inc. Transdermal penetrant formulations for vitamins, minerals and supplements
WO2021113410A1 (en) * 2019-12-02 2021-06-10 Ampersand Biopharmaceuticals, Inc. Transdermal penetrant formulations for vitamins, minerals and supplements
WO2022023822A1 (en) * 2020-07-30 2022-02-03 Indoco Remedies Limited A stable ophthalmic composition of posaconazole
US20230302032A1 (en) * 2020-08-04 2023-09-28 Harrow Ip Llc Antibacterial compositions and methods for fabricating thereof
US20220112208A1 (en) * 2020-10-08 2022-04-14 King Abdullah University Of Science And Technology Compounds with antiinflammatory activity and methods of use thereof
CN113583950A (zh) * 2021-08-06 2021-11-02 合肥滴碧云生物科技有限公司 一种制备干细胞活性因子的方法及其应用
CN115737654B (zh) * 2021-09-03 2025-11-21 成都瑞沐生物医药科技有限公司 一种滴眼给药预防和/或治疗白内障的眼用制剂
CN119136683A (zh) * 2022-05-02 2024-12-13 祖姆森斯有限公司 耐降解含醛组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743597A (en) * 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
FR2663850B1 (fr) * 1990-07-02 1994-01-14 Gird Galderma Composition pharmaceutique ou cosmetique contenant en association un retinouide et un sterol.
US6821774B1 (en) * 1999-06-18 2004-11-23 Cv Therapeutics, Inc. Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter ABC1
US6281774B1 (en) * 1999-09-10 2001-08-28 Sumitomo Special Metals Co., Ltd. Corrosion-resistant permanent magnet and method for producing the same
US20030162758A1 (en) * 2001-12-07 2003-08-28 Schwartz Daniel M. Treatment for age-related macular degeneration (AMD)
US7906147B2 (en) * 2006-10-12 2011-03-15 Nanoprobes, Inc. Functional associative coatings for nanoparticles
US8758802B2 (en) * 2009-12-14 2014-06-24 University Of Massachusetts Methods of inhibiting cataracts and presbyopia
SG11201500288QA (en) * 2012-07-17 2015-02-27 Univ Michigan Inhibitors of alpha-crystallin aggregation for the treatment for cataract
EP2968239B1 (en) * 2013-03-14 2019-04-24 The University of Massachusetts Methods of inhibiting cataracts and presbyopia
US10314917B2 (en) * 2013-03-15 2019-06-11 The Brigham And Women's Hospital, Inc. Targeted polymeric inflammation-resolving nanoparticles
EP3328389A1 (en) * 2015-07-27 2018-06-06 Catacore, Inc. Compositions for the treatment of cataracts

Also Published As

Publication number Publication date
AU2016321254A1 (en) 2018-04-05
CA2998134A1 (en) 2017-03-16
WO2017044659A1 (en) 2017-03-16
JP2018526423A (ja) 2018-09-13
CN108350021A (zh) 2018-07-31
US20180250313A1 (en) 2018-09-06
EP3347368A1 (en) 2018-07-18
EP3347368A4 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
HK1258588A1 (zh) 用於治療眼科疾病的化合物和製劑
IL282624A (en) Methods and compositions for the treatment of sight beard, mydriasis and other disorders of the eyes
EP3177732A4 (en) Compositions and methods for the treatment of ophthalmic diseases and conditions
IL273531A (en) Ophthalmic preparations containing latanoprost for use in the treatment of eye diseases
MX2015001250A (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
HK1218071A1 (zh) Sema3a在预防和治疗眼渗透性过高症中的抑制
IL287802A (en) Preparations and methods for the treatment of eye diseases
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
ZA202002075B (en) Compounds, compositions and methods for treatment of eye disorders and skin diseases
MX2020012011A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
ZA202003944B (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
SG11202012473UA (en) Ophthalmic compositions and methods for the treatment of eye disorders
MX2018003799A (es) Nueva composicion oftalmica que contiene rebamipida y metodo para prepararla.
HK1219654A1 (zh) 用於治疗眼科疾病和病症的方法
IL282898A (en) Ophthalmic compounds and methods for treating skin and eye diseases
IL280588A (en) Ophthalmic compositions and methods for treating eye problems and skin diseases
EP3187179A4 (en) Pharmaceutical composition for prophylaxis and/or treatment of corneal and conjunctival diseases or presbyopia containing stilbene compound as active ingredient
EP3129054A4 (en) Methods and compositions for the treatment of ocular diseases and disorders
HK40033459A (en) Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
HK40058483A (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
HK40021761A (en) Methods of preventing or treating ophthalmic diseases
HK40056006A (en) Methods and compositions for drugs to treat ophthalmic diseases
HK40019910A (en) Methods and compositions for treating allergic ocular diseases